FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029282173> ?p ?o ?g. }

• W2029282173 endingPage "608" @default.
• W2029282173 startingPage "608" @default.
• W2029282173 abstract "A 30–year-old man was diagnosed with ALL T-lineage immunophenotype, (CD7+, CD13+, CD45+, MPO-), normal karyotype, with no CNS involvement (negative lumbar puncture) and treated with a cycle of induction chemotherapy, including Vincristine, L-Asparaginase, and Adriamycin, with complete morphological remission. Two consolidation cycles were then administered, followed by maintenance chemotherapy with oral 6-Mecaptopurine (6-MP) and Methotrexate (MTX). As a matched bone marrow donor was not detected, the patient could not receive a stem cells transplantation. Hence, as expected, three years after diagnosis, because of the development of hyperleukocytosis (WBC 22,500/mm3) a first relapse was documented, with the presence of translocation (5;14) in 30 out of 30 metaphases. The patient underwent four cycles of savage chemotherapy, obtaining a second complete morphologic and cytogenetic remission after which he was treated with steroids, MTX, and 6-MP, as maintenance. Six months later, a second relapse occurred, and he received a cycle of chemotherapy with Nelarabine at the adult standard dosage (1,500 mg/sqm/daily on days 1, 3, and 5), which was well-tolerated. The iatrogenic bone marrow aplasia was complicated by two febrile episodes, fully resolved with antibacterial therapy, and by liver toxicity (Grade III according to WHO classification) characterized by increased cytonecrosis indexes. As a complete remission was documented, 28 days later the patient received a second cycle of Nelarabine, at the same dosage. On the third day of therapy, the patient reported the onset of severe paresthesias in his legs, bilaterally, rapidly extended to the anterior abdominal wall and to the gluteus skin. Moreover, he revealed a significant defect in maintaining equilibrium and a reduced ability in walking. A neurologic detailed examination showed a strong-force defect, especially involving legs, and a severe difficulty in standing. Lasègue sign was negative, whereas Babinski sign was detected, bilaterally. Neither force nor sensitivity defects were found at his upper arms. Alterations of urinary and bowel functions were also reported. Based on the clinical suspicion of a massive spinal cord pressure, a lumbo-sacral MRI was immediately performed, which showed, at the level of the fifth dorsal vertebra, an alteration of the intra-marrow signal, with longitudinal extension of 2 cm, and anteroposterior and lateral diameter of 0.6 and 0.8 cm, respectively (Image 1). This radiological image was consistent with transverse acute myelitis; a lumbar puncture was performed, which was negative for both CNS leukemic and infective involvement, and for ischemic damage. Therefore, the patient received steroid intravenous therapy, with only a mild and transitory improvement of the paresthesias, and no change on equilibrium and autonomic defects. A MRI with an angiographic detailed study, repeated seven days later, showed no changes. These symptoms did not further improve despite intensive rehabilitation physiotherapy. The patient maintained complete morphologic remission for 8 months, without therapy. Having ruled out ischemic and hemorrhagic etiology, and a leukemic infiltration, the worsening of sensory and motor defects and the rapid loss of autonomic functions were most likely related to cumulative drug toxicity, mainly ascribable to the administration of Nelarabine. Nelarabine is a new purine analogue, approved by FDA for the treatment of patients with T-ALL and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following at least two chemotherapy regimens. Neurologic toxicity is dose limiting for both pediatric and adult patients [1]. Major neurologic adverse events in adult population, usually include Grade I–II somnolence, dizziness, hypoesthesia, headache, paresthesia, and depressed level of consciousness. So far, rare cases of Grade III peripheral neurological disorders or ataxia have been described. Despite the high efficacy of Nelarabine [2], neurological toxicity should always be considered and carefully monitored during treatment. To the best of our knowledge, we have reported here the first case of a T-ALL patient with a lasting hematological response induced by Nelarabine, which was associated with severe and irreversible neurological toxicity, consistent with a complete paraplegia. Sagittal T2 image of the thoracic spine demonstrates abnormal hypointense marrow signal in the vertebral bodies consistent with leukemic infiltration. In addition, there is abnormal hyperintense T2 signal in the mid-thoracic spinal cord at T5 consistent with transverse myelitis (arrow)." @default.
• W2029282173 created "2016-06-24" @default.
• W2029282173 creator A5000893813 @default.
• W2029282173 creator A5023456714 @default.
• W2029282173 creator A5042328462 @default.
• W2029282173 creator A5044224344 @default.
• W2029282173 creator A5044624520 @default.
• W2029282173 creator A5060457186 @default.
• W2029282173 creator A5072253025 @default.
• W2029282173 creator A5073761054 @default.
• W2029282173 date "2010-03-22" @default.
• W2029282173 modified "2023-10-03" @default.
• W2029282173 title "Complete paraplegia after Nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient" @default.
• W2029282173 cites W2085453248 @default.
• W2029282173 cites W2126136473 @default.
• W2029282173 doi "https://doi.org/10.1002/ajh.21719" @default.
• W2029282173 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20658590" @default.
• W2029282173 hasPublicationYear "2010" @default.
• W2029282173 type Work @default.
• W2029282173 sameAs 2029282173 @default.
• W2029282173 citedByCount "29" @default.
• W2029282173 countsByYear W20292821732012 @default.
• W2029282173 countsByYear W20292821732013 @default.
• W2029282173 countsByYear W20292821732014 @default.
• W2029282173 countsByYear W20292821732015 @default.
• W2029282173 countsByYear W20292821732016 @default.
• W2029282173 countsByYear W20292821732017 @default.
• W2029282173 countsByYear W20292821732020 @default.
• W2029282173 countsByYear W20292821732021 @default.
• W2029282173 countsByYear W20292821732022 @default.
• W2029282173 countsByYear W20292821732023 @default.
• W2029282173 crossrefType "journal-article" @default.
• W2029282173 hasAuthorship W2029282173A5000893813 @default.
• W2029282173 hasAuthorship W2029282173A5023456714 @default.
• W2029282173 hasAuthorship W2029282173A5042328462 @default.
• W2029282173 hasAuthorship W2029282173A5044224344 @default.
• W2029282173 hasAuthorship W2029282173A5044624520 @default.
• W2029282173 hasAuthorship W2029282173A5060457186 @default.
• W2029282173 hasAuthorship W2029282173A5072253025 @default.
• W2029282173 hasAuthorship W2029282173A5073761054 @default.
• W2029282173 hasBestOaLocation W20292821731 @default.
• W2029282173 hasConcept C126322002 @default.
• W2029282173 hasConcept C141071460 @default.
• W2029282173 hasConcept C2776694085 @default.
• W2029282173 hasConcept C2776755627 @default.
• W2029282173 hasConcept C2778461978 @default.
• W2029282173 hasConcept C2778904437 @default.
• W2029282173 hasConcept C2779429289 @default.
• W2029282173 hasConcept C2780007613 @default.
• W2029282173 hasConcept C2781059491 @default.
• W2029282173 hasConcept C2909962599 @default.
• W2029282173 hasConcept C71924100 @default.
• W2029282173 hasConcept C90924648 @default.
• W2029282173 hasConceptScore W2029282173C126322002 @default.
• W2029282173 hasConceptScore W2029282173C141071460 @default.
• W2029282173 hasConceptScore W2029282173C2776694085 @default.
• W2029282173 hasConceptScore W2029282173C2776755627 @default.
• W2029282173 hasConceptScore W2029282173C2778461978 @default.
• W2029282173 hasConceptScore W2029282173C2778904437 @default.
• W2029282173 hasConceptScore W2029282173C2779429289 @default.
• W2029282173 hasConceptScore W2029282173C2780007613 @default.
• W2029282173 hasConceptScore W2029282173C2781059491 @default.
• W2029282173 hasConceptScore W2029282173C2909962599 @default.
• W2029282173 hasConceptScore W2029282173C71924100 @default.
• W2029282173 hasConceptScore W2029282173C90924648 @default.
• W2029282173 hasIssue "8" @default.
• W2029282173 hasLocation W20292821731 @default.
• W2029282173 hasLocation W20292821732 @default.
• W2029282173 hasOpenAccess W2029282173 @default.
• W2029282173 hasPrimaryLocation W20292821731 @default.
• W2029282173 hasRelatedWork W1953895440 @default.
• W2029282173 hasRelatedWork W2019647702 @default.
• W2029282173 hasRelatedWork W2048190719 @default.
• W2029282173 hasRelatedWork W2129922243 @default.
• W2029282173 hasRelatedWork W2252336101 @default.
• W2029282173 hasRelatedWork W2414158663 @default.
• W2029282173 hasRelatedWork W2414900200 @default.
• W2029282173 hasRelatedWork W2424848057 @default.
• W2029282173 hasRelatedWork W2428376671 @default.
• W2029282173 hasRelatedWork W2418889640 @default.
• W2029282173 hasVolume "85" @default.
• W2029282173 isParatext "false" @default.
• W2029282173 isRetracted "false" @default.
• W2029282173 magId "2029282173" @default.
• W2029282173 workType "article" @default.